ST-067 + obinutuzumab

**ST-067 + obinutuzumab** is a combination therapy explored in clinical trials for advanced solid tumors and hematologic cancers. - **ST-067** is a decoy-resistant IL-18, engineered to evade inhibition by IL-18 binding protein (IL-18BP), its natural decoy receptor. This allows IL-18 activity to persist, promoting the activation and cytotoxicity of CD8+ T cells and natural killer cells, enhancing anti-tumor immunity. - **Obinutuzumab** is a humanized monoclonal antibody targeting CD20 on B cells, used primarily in the treatment of chronic lymphocytic leukemia (CLL) and follicular lymphoma. It induces B-cell death via antibody-dependent cellular cytotoxicity, direct cytotoxicity, and complement-dependent cytotoxicity. The combination is being investigated for synergy in immune activation and anti-cancer efficacy.

Brand names

Gazyva

Other names

Decoy-Resistant IL-18obinutuzumab